PGO: A urine metabolite of styrene and ethylbenzene
Phenyl glyoxylic acid (often abbreviated PGO or PGA) is a small organic acid your body makes when it breaks down certain aromatic solvents, mainly styrene and ethylbenzene. Those parent chemicals show up in fiberglass and resin work, polystyrene plastics, some industrial solvents and coatings, fuel exhaust, and cigarette smoke. The most common exposure route is breathing indoor or workplace air; ingestion and skin contact can contribute. Labs typically measure PGO in urine, sometimes alongside mandelic acid, which together reflect recent exposure rather than long‑term body burden. Because these metabolites clear relatively quickly, a spot urine sample captures what your body has processed over roughly the last day or two.
Why it matters: styrene and ethylbenzene can affect the nervous system (think headaches, dizziness, slowed reaction time), irritate eyes and airways, and add workload to the liver as it processes and neutralizes them. Your body absorbs these solvents, metabolizes them in the liver via oxidative enzymes, and excretes the downstream acids in urine. PGO itself is not the toxin; it is a practical, validated biomarker for the exposure. Occupational health agencies have long used urinary metabolite testing to monitor workers around resins and reinforced plastics, reflecting a substantial evidence base in real-world settings, though health implications at low community levels continue to be studied.
Why a styrene/ethylbenzene biomarker is useful
Testing translates an invisible exposure into a number you can interpret. If you have intermittent contact — say, a weekend DIY epoxy project in a garage with poor airflow — PGO can spike and then fall as your body clears the metabolites. Persistent highs, especially when samples are collected at similar times of day, suggest ongoing exposure from workplace tasks, indoor air with limited ventilation, products that off‑gas, or chronic smoke exposure. For people with unexplained headaches, fatigue after short shifts, or irritant symptoms at work, a PGO result can help connect the dots between environment and physiology. It is also useful when planning a pregnancy or during pregnancy, when limiting solvent exposure is a priority for maternal comfort and fetal safety based on precautionary guidance.
Big picture: a single PGO value is a snapshot. Patterns over time — paired with symptoms, job routines, and other environmental biomarkers — paint the best picture. Seeing PGO alongside general health markers (liver enzymes, kidney function) and simple context like hydration and timing helps distinguish a transient spike from a sustained pattern that merits further evaluation with your clinician.
Think of PGO as your exposure odometer for specific solvents. Spend a Saturday helping a friend repair a fiberglass boat without great ventilation and your next‑day PGO may climb. Switch to a workspace with better airflow and you might see it drift back toward baseline. For anyone who has noticed a “workshop headache” or slower workout recovery after time around resins or exhaust, tying those experiences to measured changes can be validating.
Reading a PGO result
Labs report urine PGO using population reference data, often correcting for creatinine to account for how dilute or concentrated your urine is. For environmental solvents, lower values are generally preferable when achievable, and a clinician's interpretation improves when you repeat testing in a consistent window (for example, end of shift at the end of the workweek) so you are comparing like with like. Because PGO clears fairly quickly, results mainly reflect recent exposure.
Relatively lower values usually indicate limited recent contact with styrene or ethylbenzene and a low likelihood of short‑term irritant or neurologic effects. In daily life, that might align with good ventilation in a workshop, little time around exhaust or smoke, or product choices that do not rely on these solvents. In pregnancy and early childhood settings, lower levels are reassuring signals that current air and product exposures are modest.
Relatively higher values can flag recent or ongoing exposure and a greater workload on the liver and kidneys as they process and excrete solvent metabolites. People often notice symptoms in the same time frame — mild headaches, “spacey” concentration, eye or throat irritation — especially after time in an enclosed space with resins, paints, or exhaust. Very high or repeat elevations suggest revisiting likely sources in your environment or work practices and discussing whether additional testing or workplace controls are appropriate. It is also normal for hydration to influence any spot urine result; creatinine‑corrected reporting helps, but consistency in sampling still matters.
What can shift a PGO reading
As with any biomarker, PGO is most powerful when interpreted, not just read. It cannot localize the exact source, and it does not measure cumulative lifetime risk. Some people metabolize solvents differently, influenced by genetics, smoking, and co‑exposures, which can shift the balance between metabolites without changing health risk in a simple way. The research base is strongest in occupational settings with higher exposures; for low community levels, associations with long‑term outcomes are more modest and continue to be studied. Still, decades of workplace monitoring show that tracking urinary metabolites is a reliable way to quantify recent exposure and verify whether changes in environment or practice are moving you in the right direction.
What a PGO test can and can't tell you
Context matters most. PGO is a specific biomarker for exposure, but it does not by itself distinguish whether the source was styrene versus ethylbenzene, nor does a single number predict long‑term outcomes. When you line up PGO with other environmental metrics, general labs, and the story of your week — travel, a big resin job, time in traffic, secondhand smoke — you get a clear direction of travel. Over time, that integrated view helps separate one‑off blips from persistent patterns and supports smarter, safer choices with your clinician’s guidance.
If your results are repeatedly elevated, that is a good prompt to review possible sources and discuss next steps with a clinician familiar with occupational and environmental health. If they are low or trending down after changes, that is a sign your environment is supporting your goals.
FAQs
This test measures phenylglyoxylic acid (PGO) in urine — a metabolite and exposure marker of styrene. It reflects recent absorption and hepatic metabolism of styrene from occupational or environmental sources. Elevated urinary PGO indicates higher recent styrene uptake and is used, often alongside mandelic acid, to estimate the magnitude of exposure.
Consider testing for phenyl glyoxylic acid (PGO) if you may be exposed to styrene or ethylbenzene (e.g., work with fiberglass/resins, plastics, rubber, boat/auto shops, recent renovations, heavy solvent use, or frequent secondhand smoke) or if you have ongoing symptoms like headaches, dizziness, or eye/throat irritation. It’s also reasonable when pregnant or trying to conceive, or to verify that exposure-reduction steps are working.
PGO is a urine marker of these solvents; it’s best interpreted alongside mandelic acid and your symptoms/setting. Aim for a first-morning urine with creatinine correction, and consider retesting after remediation. If none of the above applies, routine PGO screening isn’t usually necessary.
Typically you should have a baseline test once to assess exposure to phenyl glyoxylic acid (PGO); if levels are elevated, arrange periodic follow-up testing as recommended by your clinician to monitor trends, and retest after significant lifestyle or environmental changes—for example, “after changing household products” or “following detoxification efforts.”
Phenyl glyoxylic acid (PGO) test results can be affected by several factors including timing of sample collection (time since exposure), recent exposure from food, air, water or products containing relevant precursors, individual metabolism and genetic differences, hydration status (dilution/concentration of urine), and the sample type used (urine versus blood); certain medications or supplements may also influence PGO readings.
No fasting is usually required for urinary phenylglyoxylic acid (PGO) testing, but you should follow any specific instructions from the laboratory or clinician. A first‑morning urine sample can reduce day‑to‑day variability and dilution effects and is often preferred; if you cannot provide a first‑morning void, avoid excessive fluid intake immediately before the sample to reduce dilution.
If the aim is to assess background exposure rather than a recent spike, try to avoid known sources of styrene/solvent exposure (for example: occupational solvents, paints, adhesives, fuels, cigarette smoke) for a short period before sampling if feasible; check with the testing provider for how long. Document and report any recent contact with plastics, personal‑care products, pesticides, solvents, paints, adhesives or other chemical products, and note the timing (hours/days) of that exposure when you submit the sample.
Phenyl glyoxylic acid (PGO) testing is generally reliable as a biomarker of exposure when samples are collected and analyzed correctly; however it is best interpreted as an indicator of recent exposure rather than long‑term body burden. Properly validated laboratory methods provide accurate qualitative and quantitative results, but PGO concentrations mainly reflect exposures occurring in the preceding hours to a couple of days rather than accumulated cumulative dose over months or years.
Accuracy depends strongly on sample timing (when the specimen is taken relative to exposure), the laboratory method used (targeted mass spectrometry methods are more sensitive and accurate than less specific assays), and consistent, correct collection, storage and handling to avoid contamination or degradation. For the best results, use standardized collection protocols and a laboratory that reports method validation and quality controls (e.g., mass spectrometry-based analysis).
References
- Chua, S. C., Lee, B. L., Liau, L. S., & Ong, C. N. (1993). Determination of mandelic acid and phenylglyoxylic acid in the urine and its use in monitoring of styrene exposure. Journal of Analytical Toxicology, 17(3), 129-132. https://doi.org/10.1093/jat/17.3.129
- Capella, K. M., Roland, K., Geldner, N., Rey deCastro, B., De Jesús, V. R., van Bemmel, D., & Blount, B. C. (2019). Ethylbenzene and styrene exposure in the United States based on urinary mandelic acid and phenylglyoxylic acid: NHANES 2005-2006 and 2011-2012. Environmental Research, 171, 101-110. https://doi.org/10.1016/j.envres.2019.01.018
- Calafat, A. M., & Needham, L. L. (2008). Factors affecting the evaluation of biomonitoring data for human exposure assessment. International Journal of Andrology, 31(2), 139-143. https://doi.org/10.1111/j.1365-2605.2007.00826.x
- Barr, D. B., Wilder, L. C., Caudill, S. P., Gonzalez, A. J., Needham, L. L., & Pirkle, J. L. (2005). Urinary creatinine concentrations in the U.S. population: Implications for urinary biologic monitoring measurements. Environmental Health Perspectives, 113(2), 192-200. https://doi.org/10.1289/ehp.7337
- Centers for Disease Control and Prevention. (2021). Fourth national report on human exposure to environmental chemicals, updated tables, March 2021. https://stacks.cdc.gov/view/cdc/105345






































.avif)

